Telik (TELK:Nasdaq - commentary - research) reported positive interim data from an early-stage study evaluating its Telcyta in combination with chemotherapy in treating advanced non-small-cell lung cancer.
The company, reporting the results at the annual meeting of the American Society of Clinical Oncology, said that in the trial a 62% objective response rate, including one complete response and seven partial responses, and a disease stabilization rate of 92% were observed among the patients who could be evaluated.
At the time of analysis, all 13 patients in the Phase I stage of the trial could be evaluated for safety and efficacy. Four dose levels of Telcyta were studied (400-, 500-, 750- and 1,000-milligram), along with standard doses of the chemo drugs carboplatin and paclitaxel administered every three weeks.
phase 1 means we are a ways off...even fast tracking is still a year and a half usually...
-------------------- Don't envy the happiness of those who live in a fool's paradise.
IP: Logged |
posted
Celgene (CELG), Genentech (DNA), Pfizer (PFE), and Onyx Pharmaceuticals (ONXX) will report about their new cancer-fighting drugs. Positive results could push shares of these companies higher. However, this may already be priced in by investors who bought earlier in learning that the companies planned to present in the Orlando conference.
-------------------- The light of truth is blinding to most.
More comforting to look only at the shadows of falseness.
IP: Logged |
posted
Cancer news from ASCO's Annual meeting........
Toremifene and advanced cancer care treament, care,and prevention reported from the American Society of clinical Oncologys [ ASCO ] annual meeting [ may 13-17, 2005 in Orlando FL.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
